News News List. News Search Select your country Global Corporate Website. Watson Pharmaceuticals announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, effective immediately.
In this position, Mr. Stewart will have responsibility for global manufacturing, supply chain, quality and technic You are currently not logged in to my.
Your changes will in fact be stored however can be lost at all times. Watson Completes Actavis Acquisition. Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab. Watson Names Robert A. We are focused on the development and commercialization of more complex products, including moving beyond modified-release solid-dosage products into complex transdermals, topicals, and ophthalmics, as well as semi-solid, inhalation, and complex injectable products.
On April 25, , we announced that we had entered into a definitive agreement to acquire privately held Actavis. As a result of this proposed acquisition, which is expected to close in the fourth quarter of , Watson will become the third largest global generics company. The combined company will hold a top 3 position in 12 markets and a top 5 market position in 15 markets.
Save my name, email, and website in this browser for the next time I comment. By Thomas Sullivan Last updated May 4, Nov 3, Nov 1, Oct 26,
0コメント